You are here

Article Text

Article menu
Download PDFPDF
Review
Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy
  1. Lindsay Hennah,
  2. Michael Seckl and
  3. Ehsan Ghorani
  1. Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK
  1. Correspondence to Dr Ehsan Ghorani, Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, London, UK; e.ghorani{at}imperial.ac.uk; Professor Michael Seckl, Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK; m.seckl{at}imperial.ac.uk

Abstract

The discovery that anti-programmed death-1 antibody (anti-PD-1) immunotherapy can cure patients with multidrug-resistant gestational trophoblastic neoplasia provides a new powerful and low toxicity treatment. This heralds an era within which the majority of patients, including those with previously difficult to treat disease, can expect to achieve long-term remission. This development should prompt a rethink of how patients with this rare disease are managed, focusing on maximizing cure rate with minimal exposure to toxic chemotherapy.

  • Gestational Trophoblastic Disease

https://doi.org/10.1136/ijgc-2022-003771

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors EG and MS conceived the article and LH wrote the first draft. All authors provided critical intellectual input, revised and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.